tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Takahashi K et al. Safety and efficacy of once-daily modified-release tacrolimus in kidney transplant recipients: interim analysis of multicenter postmarketing surveillance in Japan. 2014 Transplant. Proc. pmid:24655975
Christe W Neurological disorders in liver and kidney transplant recipients. 1994 Transplant. Proc. pmid:7527953
Kahan BD Cyclosporine: the base for immunosuppressive therapy--present and future. 1993 Transplant. Proc. pmid:7679819
Bersztel A et al. Deoxyspergualin is synergistic with cyclosporin A, but not with FK506 in a rat heart allograft transplantation model. 1995 Transplant. Proc. pmid:8540095
Starzl TE FK 506 versus cyclosporine. 1993 Transplant. Proc. pmid:7679820
Fukuzaki T et al. Nonvascularized islet xenograft rejection in a mouse-to-rat combination where the vascularized heart is rapidly rejected. 1994 Transplant. Proc. pmid:7513472
Yabuuchi H et al. Prominent prolongation of islet xenograft survival in combination therapy with FK 506 and 15-deoxyspergualin. 1991 Transplant. Proc. pmid:1703718
Facundo C et al. Results of a triple induction regime with tacrolimus, mycophenolate mofetil, and prednisone in renal transplantation. 2002 Transplant. Proc. pmid:11959203
McDiarmid S et al. One hundred children treated with tacrolimus after primary orthotopic liver transplantation. 1998 Transplant. Proc. pmid:9636564
Fraile P et al. Non-skin solid tumors as a cause of morbidity and mortality after liver transplantation. 2009 Jul-Aug Transplant. Proc. pmid:19715943
Rath T and Küpper M Comparison of inosine-monophosphate-dehydrogenase activity in patients with enteric-coated mycophenolate sodium or mycophenolate mofetil after renal transplantation. 2009 Jul-Aug Transplant. Proc. pmid:19715967
Lee KK et al. Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy. 1990 Transplant. Proc. pmid:1689908
Ueda Y et al. Induction of graft acceptance after dog kidney or liver transplantation. 1990 Transplant. Proc. pmid:1689909
Ueno T et al. Renal dysfunction following adult intestinal transplant under tacrolimus-based immunosuppression. 2006 Jul-Aug Transplant. Proc. pmid:16908274
Sessa A et al. Immunosuppressive agents and metabolic factors of cardiovascular risk in renal transplant recipients. 2009 Transplant. Proc. pmid:19460510
Spagnoletti G et al. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine. 2009 Transplant. Proc. pmid:19460509
Abu-Elmagd KM et al. Monitoring and treatment of intestinal allograft rejection in humans. 1993 Transplant. Proc. pmid:7680150
Fujikawa K et al. Effects of tacrolimus on rat thymic epithelial cells. 2000 Transplant. Proc. pmid:11120046
McCauley J et al. FK 506 in the management of nephrotic syndrome after renal transplantation. 1993 Transplant. Proc. pmid:7680154
Crespo-Leiro MG Calcineurin inhibitors in heart transplantation. 2005 Transplant. Proc. pmid:16386614
Farghali H et al. A biochemical and 31P-NMR investigation of the effect of FK 506 and cyclosporine pretreatment on immobilized hepatocytes perifused with ethanol. 1991 Transplant. Proc. pmid:1721284
Jordan ML et al. Tacrolimus-based immunosuppression in pediatric renal transplantation. 1999 Transplant. Proc. pmid:10576039
Farghali H et al. FK 506 modulates D-galactosamine-induced hepatitis in rats. 1991 Transplant. Proc. pmid:1721285
Harrison DM et al. Reduction in hospital stay after liver transplantation. 1996 Transplant. Proc. pmid:8623451
Andrews WS et al. Comparison of cyclosporine- vs tacrolimus-based immunosuppression in pediatric liver transplantation. 1996 Transplant. Proc. pmid:8623452
Armenta Bautista A et al. Renal Transplantation in Second-Level Private Hospitals in the State of Mexico. 2018 Transplant. Proc. pmid:29579825
Sathyan S et al. A case of recurrent immunotactoid glomerulopathy in an allograft treated with rituximab. 2009 Transplant. Proc. pmid:19917422
Schulz T et al. Tacrolimus/mycophenolate mofetil/steroid-based immunosuppression after pancreas-kidney transplantation with single shot antithymocyte globulin. 1998 Transplant. Proc. pmid:9636623
Marzoa-Rivas R et al. Conversion of heart transplant patients from standard to sustained-release tacrolimus requires a dosage increase. 2010 Transplant. Proc. pmid:20970591
Lodewijk L et al. Effect of liver regeneration on the pharmacokinetics of immunosuppressive drugs. 2009 Jan-Feb Transplant. Proc. pmid:19249561
Metcalfe S et al. FK 506 and cyclosporine A: early effects on activation and gene induction in mouse spleen cells. 1990 Transplant. Proc. pmid:1697107
Pan F et al. FK 506 prolongs survival of liver but not heart mouse-to-rat vascularized xenografts. 1994 Transplant. Proc. pmid:7518113
Florman S et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. 2005 Transplant. Proc. pmid:15848672
Kato T et al. Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study. 2005 Transplant. Proc. pmid:15848674
Frank B et al. Neurotoxicity of FK 506 in liver transplant recipients. 1993 Transplant. Proc. pmid:7682355
Söderdahl G et al. FK 506 improves recovery of bile secretion following orthotopic liver transplantation in man. 1995 Transplant. Proc. pmid:7533362
Matsuura T et al. Beneficial immunosuppressive effect of combined use of FK 506 and cyclosporine assessed by proliferative responses of cloned human T cells. 1991 Transplant. Proc. pmid:1721316
Wynn C et al. High level of TGF-beta in organ transplantation might be due to rejection rather than calcineurin inhibitor medication. 2002 Transplant. Proc. pmid:12176408
Schumacher G et al. Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. 2002 Transplant. Proc. pmid:12176410
Mortensen DM et al. Calcineurin activity in tacrolimus-treated renal transplant patients early after and 5 years after transplantation. 2006 Transplant. Proc. pmid:17098028
Loucaidou M et al. Late steroid withdrawal for renal transplant recipients on tacrolimus and MMF is safe. 2005 Transplant. Proc. pmid:15919469
Ochiai T et al. Japanese multicenter studies of FK 506 in renal transplantation. Japanese FK 506 Study Group. 1995 Transplant. Proc. pmid:7533419
Saito S et al. The pattern of rejection and susceptibility to different kinds of immunosuppression after combined liver, duodenum, and pancreas transplantation in swine--immunosuppressive drugs versus ex vivo immunomodulation of the allograft. 1995 Transplant. Proc. pmid:7533420
Morel P et al. Liver retransplantation in adults: overall results and determinant factors affecting the outcome. 1991 Transplant. Proc. pmid:1721349
Aktürk S et al. Average Tacrolimus Trough Level in the First Month After Transplantation May Predict Acute Rejection. 2017 Transplant. Proc. pmid:28340806
Langrehr JM et al. First results from a prospective randomized trial comparing steroid-free induction therapy with tacrolimus and MMF versus tacrolimus and steroids in patients after liver transplantation for HCV. 2002 Transplant. Proc. pmid:12176487
Hamano I et al. Condyloma Acuminata of the Urethra in a Male Renal Transplant Recipient: A Case Report. 2018 Transplant. Proc. pmid:30316397
Shapiro R et al. Kidney transplantation under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1703352
Zucker K et al. Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving Prograf and CellCept in combination therapy. 1997 Feb-Mar Transplant. Proc. pmid:9123027
Iaria G et al. Switch from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in kidney transplantation. 2011 Transplant. Proc. pmid:21620043
Di Benedetto F et al. University of Modena experience in HIV-positive patients undergoing liver transplantation. 2011 Transplant. Proc. pmid:21620066
Ronchetti F et al. Mucosal hyaluronic acid quantification in small bowel transplantation in pigs. 1996 Transplant. Proc. pmid:8907950
Sun CK et al. Intensive care after orthotopic liver transplantation. 1994 Transplant. Proc. pmid:7520627
Yin DP et al. Efficacy of FK506, leflunomide, anti-CD4, and CTLA4IG treatments in rat to mouse pancreas xenograft transplantation. 2000 Transplant. Proc. pmid:10936320
Song Z et al. Protective effect of FK-506 in pig-to-rat islet xenotransplantation is abrogated by prednisolone. 2000 Transplant. Proc. pmid:10936332
Prasad SJ et al. In vitro effects of cyclosporine and FK 506 on the renal cortex. 1991 Transplant. Proc. pmid:1721380
Witzigmann H et al. Immunosuppression with sirolimus/tacrolimus combination in pancreas transplantation: 1-year results. 2002 Transplant. Proc. pmid:12493472
Yamada K et al. Short-term FK 506-induced morphological changes in rat kidneys. 1991 Transplant. Proc. pmid:1721381
Sola E et al. Low-dose and rapid steroid withdrawal in renal transplant patients treated with tacrolimus and mycophenolate mofetil. 2002 Transplant. Proc. pmid:12176537
San Miguel C et al. Immunosuppression Strategies in the Treatment of Hepatocellular Carcinoma in Virgen de las Nieves University Hospital. 2015 Transplant. Proc. pmid:26518930
Miura K et al. Development of the Intestinal Transplantation Model With Major Histocompatibility Complex Inbred CLAWN Miniature Swine. 2016 Transplant. Proc. pmid:27320612
Lee HK et al. Expression of Endoplasmic Reticulum-Mediated Stress Proteins in FK506-Treated T-Lymphocytes. 2016 Transplant. Proc. pmid:27320607
Song Z et al. FK 506 prevents islet xenograft rejection: a study in the pig-to-rat model. 1999 Feb-Mar Transplant. Proc. pmid:10083437
Uchida J et al. Conversion of stable kidney transplant recipients from a twice-daily prograf to a once-daily tacrolimus formulation: a short-term study on its effects on glucose metabolism. 2012 Transplant. Proc. pmid:22310596
Toraishi T et al. Falsely abnormally elevated blood trough concentration of tacrolimus measured by antibody-conjugated magnetic immunoassay in a renal transplant recipient: a case report. 2012 Transplant. Proc. pmid:22310597
Yasunami Y et al. Effects of a novel immunosuppressive agent, FK-506, on islet allograft survival in the rat. 1989 Transplant. Proc. pmid:2468234
Stratta RJ Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: a multi-center report. The FK/MMF Multi-Center Study Group. 1997 Feb-Mar Transplant. Proc. pmid:9123463
Jonas S et al. Posttransplant malignancy and newer immunosuppressive protocols after liver transplantation. 1996 Transplant. Proc. pmid:8962257
Madariaga JR et al. The long-term efficacy of multivisceral transplantation. 2000 Transplant. Proc. pmid:10995918
Tze WJ et al. Long-term survival of islet allografts in diabetic rats treated with FK 506. 1991 Transplant. Proc. pmid:1721411
Shinozuka N et al. Correlation between simplified immunocompetence assay and clinical graft states in kidney or liver transplant recipients. 1996 Transplant. Proc. pmid:8658649
McCarter JF et al. FK 506 protects brain tissue in animal models of stroke. 2001 Transplant. Proc. pmid:11377571
Baran DA et al. Predictors of early renal insufficiency in cardiac transplant recipients initiated on tacrolimus. 2002 Transplant. Proc. pmid:12176609
Zhou S et al. Tacrolimus enhances the invasion potential of hepatocellular carcinoma cells and promotes lymphatic metastasis in a rat model of hepatocellular carcinoma: involvement of vascular endothelial growth factor-C. 2011 Transplant. Proc. pmid:21911157
Kauffman HM et al. Drug regimens affect cadaveric kidney graft survival. 2001 Feb-Mar Transplant. Proc. pmid:11267176
Sicilia-Castro D et al. Reconstruction of a severe facial defect by allotransplantation in neurofibromatosis type 1: a case report. 2011 Transplant. Proc. pmid:21911174
Dudley CR Conversion at first rejection: a prospective trial comparing cyclosporine microemulsion with tacrolimus in renal transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267179
Hummel AD et al. Application of artificial neural networks in renal transplantation: classification of nephrotoxicity and acute cellular rejection episodes. 2010 Transplant. Proc. pmid:20304167
Gnatta D et al. Use of tacrolimus and the development of posttransplant diabetes mellitus: a Brazilian single-center, observational study. 2010 Transplant. Proc. pmid:20304169
Ettenger RB New immunosuppressive agents in pediatric renal transplantation. 1998 Transplant. Proc. pmid:9723350
Ventura E et al. Calcineurin Inhibitor Determination in Whole Blood With the RXL Dimension Analyzer: A Useful Tool for Immunosuppressive Drug Monitoring. 2009 Transplant. Proc. pmid:19328963
Falkenstein K and Dunn S Tacrolimus to cyclosporine microemulsion formulation conversion in the pediatric liver transplant patient. 1998 Transplant. Proc. pmid:9723354
Sanghvi A et al. FK-506 enhances cyclosporine uptake by peripheral blood lymphocytes. 1987 Transplant. Proc. pmid:2445074
van der Laan LJ et al. Results of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus. 2010 Transplant. Proc. pmid:21168740
Moray G et al. Comparison of histidine-tryptophan-ketoglutarate and University of Wisconsin in living-donor liver transplantation. 2006 Transplant. Proc. pmid:17175334
Hasegawa S et al. FK 506 and cyclosporine: effects and side effects in canine lung transplantation. 1991 Transplant. Proc. pmid:1721443
Wada H et al. Dose response to FK 506 in canine lung transplantation. 1991 Transplant. Proc. pmid:1721444
Groth CG et al. New immunosuppressive drugs in transplantation. 1993 Transplant. Proc. pmid:7689274
McMaster P and Buist L FK 506 in transplantation. 1993 Transplant. Proc. pmid:7689275
Ito T et al. Therapeutic Effect of Sirolimus for Lymphangioleiomyomatosis Remaining in the Abdominopelvic Region After Lung Transplantation: A Case Report. Transplant. Proc. pmid:26915883
van den Berg AP et al. Recurrent HCV infection reduces the requirement for tacrolimus after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267375
Kim YE and Eun SC Effect of FK506 ointment (Protopic) on rat skin allograft model. 2014 Transplant. Proc. pmid:24815165
Escartín A et al. Orthotopic small bowel transplantation in pigs without steroids. 1999 Transplant. Proc. pmid:10500720
Shingaki S et al. Graft-versus-host Disease-free, Relapse-free Survival After HLA-identical Sibling Peripheral Blood Stem Cell Transplantation With Tacrolimus-based Graft-versus-host Disease Prophylaxis in Japanese Patients. Transplant. Proc. pmid:29407317
Hutchinson IV et al. Differences in the mode of action of cyclosporine and FK 506. 1998 Transplant. Proc. pmid:9636388
Granot E et al. Monitoring of Epstein-Barr virus serology in children after liver transplant: lack of clinical correlation. 2000 Transplant. Proc. pmid:10856551
Tariciotti L et al. Everolimus and Advagraf Ab Initio in Combined Liver and Kidney Transplant With Donor-Specific Antibodies: A Case Report. 2016 Transplant. Proc. pmid:27932158
Kahu J et al. Impact of mycophenolate mofetil intolerance on early results of kidney transplantation. 2005 Transplant. Proc. pmid:16298571
Budde K et al. Tacrolimus rescue therapy in late rejection after renal transplantation: outcome after 18 months. 1998 Transplant. Proc. pmid:9636503
Friemann S et al. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. 1998 Transplant. Proc. pmid:9636504